Autoimmune Diseases  >>  Cosentyx (secukinumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Cosentyx (secukinumab) / Novartis
NURTURE 1, NCT01350804 / 2011-000102-21: Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis (RA) and an Inadequate Response to Anti-Tumor Necrosis Factor α (Anti-TNFα) Agents (CAIN457F2309 and CAIN457F2309E1)

Completed
3
551
US, Canada, Europe, RoW
AIN457, Secukinumab, Placebo, Abatacept, Orencia
Novartis Pharmaceuticals
Rheumatoid Arthritis
02/15
02/15
REASSURE2, NCT01770379 / 2011-006058-94: Secukinumab Efficacy and Safety Study in Patients With Rheumatoid Arthritis and Inadequate Response to Anti-TNFα Agents.

Terminated
3
242
Japan, US, Europe, RoW
Secukinumab (AIN457), AIN457, Placebo
Novartis Pharmaceuticals
Rheumatoid Arthritis
05/15
05/15
REASSURE-E, NCT01901900 / 2013-000944-25: Safety and Efficacy of Extended Treatment With Secukinumab in Anti-TNF Inadequate Responders in RA.

Completed
3
196
Japan, US, Canada, Europe, RoW
Secukinumab (AIN457), AIN457
Novartis Pharmaceuticals, Novartis Pharma Services AG
Rheumatoid Arthritis
05/15
05/15
NCT01377012 / 2011-000275-13: Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents

Completed
3
637
Japan, US, Canada, Europe, RoW
Secukinumab (AIN457), AIN457, Placebo
Novartis Pharmaceuticals
Rheumatoid Arthritis
09/15
09/15

Download Options